Dilon Technologies, a leader in medical devices for biosurgery, breast cancer treatment, and diagnosis, announced a $9 million growth capital investment from JGB Management. This investment will support Dilon’s continued growth in double digits and operational scaling.
HEMOBLAST Bellows: HEMOBLAST Bellows is an advanced hemostatic agent utilized in a wide range of surgeries, including cardiac, general, and orthopedic procedures. And it remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST Bellows continues to redefine standards in surgical hemostasis.
MarginProbe: MarginProbe is an in-surgery and real-time breast cancer margin assessment device. And it enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. The clinical studies show MarginProbe reduces re-excision rates by 25% to 80%. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end.
Dilon’s Navigator Gamma Probe product line, which is a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. And a new and enhanced version is expected to launch by late 2025.
KEY QUOTES:
“We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide. This funding empowers us to continue delivering best-in-class innovations that improve patient care.”
George Makhoul, CEO of Dilon Technologies
“We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide.”
Brett Cohen, CEO of JGB Management
